Send to

Choose Destination
See comment in PubMed Commons below
Curr Med Res Opin. 2004 Jan;20(1):31-7.

Insulin glargine: long-acting basal insulin analog for improved metabolic control.

Author information

  • 1School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Box MED/CRC, Rochester, NY 14642, USA.


The primary aim of insulin therapy is to replace endogenous insulin secretion in patients with type 1 or type 2 diabetes in a physiologically sound manner, mimicking normal secretion patterns to adequately regulate glucose metabolism. The currently available human insulins for basal therapy--neutral protamine Hagedorn (NPH), Lente and Ultralente--and analogs such as insulin glargine, differ in pharmacokinetic properties. Clinical trial data indicate that insulin glargine may satisfy basal insulin requirements, with an improved safety profile relative to other available insulins used for basal supplementation. This review describes the unique pharmacokinetic properties and clinical efficacy of insulin glargine.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center